Douglas J. Devine Net Worth

The estimated Net Worth of Douglas Devine is at least $5.62 Million dollars as of 3 March 2023. Mr Devine owns over 1,473 units of iRhythm Technologies Inc stock worth over $2,212,424 and over the last 4 years he sold IRTC stock worth over $2,832,340. In addition, he makes $573,158 as COO and CFO & Sec. at iRhythm Technologies Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Devine IRTC stock SEC Form 4 insiders trading

Mr has made over 8 trades of the iRhythm Technologies Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 1,473 units of IRTC stock worth $172,680 on 3 March 2023.

The largest trade he's ever made was selling 10,109 units of iRhythm Technologies Inc stock on 7 July 2022 worth over $1,154,650. On average, Mr trades about 2,248 units every 55 days since 2020. As of 3 March 2023 he still owns at least 29,566 units of iRhythm Technologies Inc stock.

You can see the complete history of Mr Devine stock trades at the bottom of the page.

Mr. Douglas J. Devine biography

Douglas J. Devine is the COO, CFO & Sec. at iRhythm Technologies Inc.

What is the salary of Mr Devine?

As the COO and CFO & Sec. of iRhythm Technologies Inc, the total compensation of Mr Devine at iRhythm Technologies Inc is $573,158. There are 6 executives at iRhythm Technologies Inc getting paid more, with Kevin King having the highest compensation of $4,774,140.

How old is Mr Devine?

Mr Devine is 51, he's been the COO and CFO & Sec. of iRhythm Technologies Inc since . There are 17 older and 6 younger executives at iRhythm Technologies Inc. The oldest executive at iRhythm Technologies Inc is Ralph Snyderman, 80, who is the Independent Director.

What's Mr Devine's mailing address?

Douglas's mailing address filed with the SEC is C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH ST #600, SAN FRANCISCO, CA, 94103.

Insiders trading at iRhythm Technologies Inc

Over the last 8 years, insiders at iRhythm Technologies Inc have traded over $124,847,276 worth of iRhythm Technologies Inc stock and bought 150,000 units worth $2,550,000 . The most active insiders traders include Holdings A/S Novo, Vijay K Lathi, and Kevin M King. On average, iRhythm Technologies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,872,546. The most recent stock trade was executed by Brice Bobzien on 9 August 2024, trading 1,372 units of IRTC stock currently worth $96,506.

What does iRhythm Technologies Inc do?

irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.

Complete history of Mr Devine stock trades at iRhythm Technologies Inc

iRhythm Technologies Inc executives and stock owners

iRhythm Technologies Inc executives and other stock owners filed with the SEC include:

• Kevin King,
  President, Chief Executive Officer, Director
• David Vort,
  Executive Vice President - Sales
• Mark Day,
  Executive Vice President of Research and Development
• Kevin M. King,
  Consultant & Director
• Matthew C. Garrett,
  Advisor
• Daniel G. Wilson,
  Exec. VP of Strategy, Corp. Devel. & Investor Relations
• Douglas J. Devine,
  COO, CFO & Sec.
• David A. Vort,
  Exec. VP of Sales & Chief Commercial Officer
• Mark J. Day Ph.D.,
  Exec. VP of R&D
• Abhijit Talwalkar,
  Independent Chairman of the Board
• Mark Rubash,
  Independent Director
• Raymond Scott,
  Independent Director
• Bruce Bodaken,
  Independent Director
• Ralph Snyderman,
  Independent Director
• Cathleen Noel Merz,
  Independent Director
• Douglas Devine,
  Chief Financial Officer
• Renee Budig,
  Independent Director
• Mazi Kiani,
  Sr. VP of Quality & Regulatory
• Dietra N. Jones,
  Exec. VP of Clinical Operations
• Reyna M. Fernandez,
  Exec. VP & Chief HR Officer
• Dr. Mintu P. Turakhia M.D.,
  Chief Medical Officer & Chief Scientific Officer
• Allan B. Wilsker,
  Exec. VP of Information Technology & Customer Service
• Patrick Michael Murphy J.D.,
  Gen. Counsel
• Quentin S. Blackford,
  Pres & CEO
• Judith C. Lenane,
  Chief Clinical Officer & Exec. VP of Operations
• Kaja J. Odegard,
  VP of HR
• Marga Ortigas-Wedekind,
  Exec. VP of Marketing
• Michael J. Coyle,
  Pres, CEO & Director
• Tiba Aynechi,
  Director
• Life Science Partners L P S...,
  
• Venture Partners Xi, Lp Cro...,
  
• Matthew C. Garrett,
  Chief Financial Officer
• Life Science Partners L P S...,
  
• Holdings A/S Novo,
  10% owner
• Clercq Casper L. De,
  Director
• Michael J Coyle,
  President and CEO
• Vijay K Lathi,
  Director
• Karim Karti,
  Former Chief Operating Officer
• Derrick Sung,
  EVP, Strat Corp Development
• Mojdeh Poul,
  Director
• Brian B Yoor,
  Director
• Karen Ling,
  Director
• Mervin Smith,
  EVP Strategic Business Ops
• Marc W. Rosenbaum,
  Chief Accounting Officer
• Daniel G. Wilson,
  EVP, Corp Dev Inv Rel
• Brice Bobzien,
  Chief Financial Officer
• Quentin S. Blackford,
  President and CEO
• Minang Turakhia,
  EVP, CMO & CSO
• Reyna M Fernandez,
  EVP, Chief HR Officer
• Chad Patterson,
  Chief Commercial Officer
• Sumi Shrishrimal,
  EVP, Chief Risk Officer
• Patrick Michael Murphy,
  CBO and CLO